Ivonescimab and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

This study is exploring a new treatment option for patients with esophageal squamous cell carcinoma, a type of cancer affecting the esophagus. In China, esophageal cancer is particularly common, and current treatments like surgery and chemotherapy have not significantly lowered the death rate. For patients whose cancer has spread locally but not extensively, surgery alone often isn't enough to remove all cancer cells or prevent the disease from coming back. This study focuses on combining a new drug called Ivonescimab, which is designed to help the immune system fight cancer, with chemotherapy before surgery. The goal is to see if this combination can improve survival rates by reducing the risk of cancer returning after surgery. Participants in this study will receive Ivonescimab along with chemotherapy before undergoing surgery. Ivonescimab is given as a treatment that targets specific proteins to help the body’s immune system better attack the cancer cells. The main goal of the study is to see if this treatment approach can completely eliminate the cancer cells in the tissue that is removed during surgery, known as a Pathological Complete Response. By measuring the absence of invasive tumor cells in the removed tissues, researchers hope to determine the effectiveness of the treatment. If successful, this study could lead to better treatment strategies for patients with this type of esophageal cancer.